TWD 76.2
(-1.3%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.52 Billion TWD | 1.99% |
2022 | 1.5 Billion TWD | 25.98% |
2021 | 1.13 Billion TWD | -6.45% |
2020 | 1.37 Billion TWD | -3.31% |
2019 | 1.41 Billion TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 404.69 Million TWD | -9.92% |
2024 Q1 | 411.54 Million TWD | 58.96% |
2023 FY | - TWD | 1.99% |
2023 Q3 | 562.65 Million TWD | 23.4% |
2023 Q4 | 285.24 Million TWD | -49.3% |
2023 Q1 | 341.37 Million TWD | -7.56% |
2023 Q2 | 455.96 Million TWD | 33.57% |
2022 Q4 | 369.27 Million TWD | 0.0% |
2022 FY | - TWD | 25.98% |
2021 FY | - TWD | -6.45% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | -644.358% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | -559.639% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 1882.887% |
Synmosa Biopharma Corporation | 1 Billion TWD | -51.118% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | -161.501% |
Center Laboratories, Inc. | -175.17 Million TWD | 970.232% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -4809.772% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | -784.24% |
InnoPharmax Inc. | -62.12 Million TWD | 2553.938% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | -1103.355% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 5290.459% |
DV Biomed Co., Ltd. | 407.64 Million TWD | -273.954% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 267.118% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | -89.887% |
UniPharma Co., Ltd. | -16.25 Million TWD | 9478.528% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | -1060.906% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | -286.39% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | -567.639% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 4005.277% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -12461.895% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -1434.359% |